Figure 1 | Cancer Gene Therapy

Figure 1

From: Additive antileukemia effects by GFI1B- and BCR–ABL-specific siRNA in advanced phase chronic myeloid leukemic cells

Figure 1

Growth rate of K562 cells after transfection with BCR–ABL siRNA, GFI1B siRNA and cotreatment with both siRNAs as determined by the MTT assay. (a) Forty-eight hours after siRNA transfection, the number of viable K562 cells decreased significantly (P<0.0001). (b) Kinetics of growth inhibition of K562 cells following application of 175 pM GFI1B siRNA and 54 pM BCR–ABL siRNA or two scrambled siRNAs and/or without siRNAs is shown. Mean and s.d. are presented. The percentage of viable cells was determined by comparison with untreated or scrambled siRNA-transfected cells. BCR–ABL siRNA, breakpoint cluster region–Abelson murine leukemia oncogene small interfering RNA.

Back to article page